It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297724;](https://doi.org/10.1101/2023.11.01.23297724) this version posted November 3, 2023. The copyright holder for this preprint

Original Article

Machine learning predicts metastatic

progression using novel differentially

expressed lncRNAs as potential markers in pancreatic cancer

Hasan Alsharoh¹***

¹ "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania

*Corresponding author: hasanalsharoh@gmail.com

Abstract

 Pancreatic cancer (PC) is associated with high mortality overall. Recent literature has focused on investigating long noncoding RNAs (lncRNAs) in several cancers, but studies on their functions in PC are lacking. To identify significantly altered expression of lncRNA in PC, I collected information from The Cancer Genome Atlas (TCGA) and extracted RNA-sequencing (RNA-seq) transcriptomic profiles of pancreatic carcinomas and performed differential gene expression analysis. Out of 60,660 gene transcripts shared between 151 PC patients, I identified 38 lncRNAs that were significantly differentially expressed. To further investigate the functions of these genes, gene set enrichment analysis (GSEA) was performed on the population lncRNA panel. GSEA results revealed enrichment of several terms implicated in proliferation. To assess the contribution of these lncRNAs to metastatic progression, I used different ML algorithms, including logistic regression (LR), support vector machine (SVM), random forest classifier (RFC) and eXtreme Gradient Boosting Classifier (XGBC). Explicitly using significantly differentiated lncRNA genes and hyperparameter tuning, in addition to reducing bias through the synthetic minority oversampling technique, the accuracy of the ML models improved. Regardless, out of the four algorithms,

 both SVM and RFC were able to predict metastatic progression with 76% accuracy. To the best of my knowledge, this is the first study of its kind to identify this lncRNA panel to differentiate between nonmetastatic PC and metastatic PC, with many novel lncRNAs previously unmapped to PC. The ML 26 accuracy score reveals important involvement of the detected RNAs. Based on these findings, I suggest further investigations of this gene panel *in vitro* and *in vivo*, as they could be targeted for improved outcomes in PC patients, as well as assist in the diagnosis of metastatic progression based on RNA-seq data of primary pancreatic tumors.

31 1. Introduction

32 Pancreatic cancer (PC) is one of the deadliest cancers, with an overall five-year survival between 7.2 33 and 10% according to the literature^{1,2}. Evidence suggests that PC is often diagnosed in the late stages of 34 tumorigenesis, likely contributing to its high mortality rate³. Recent literature has provided increasing 35 evidence regarding the involvement of long noncoding RNAs (lncRNAs) in the development, invasiveness, 36 angiogenic potential, chemotherapeutic resistance and metastatic capacity of $PC⁴$.

37 LncRNAs are RNA molecules characterized by having an arbitrary lower cutoff of 200 nucleotides that 38 have been shown not to code for proteins post-transcriptionally 4.5 . LncRNAs have been shown to play 39 complex roles in biological processes in various tissues, with possible implications in DNA repair, cellular 40 proliferation, and human diseases, which made them a common target for recent literature to investigate 41 in cancer ⁶. IncRNAs have further been used as biomarkers for overcoming chemoresistance, as well as for 42 the diagnosis of several cancers, including PC $7-10$.

43 Emerging research has been able to provide evidence regarding the use of lncRNAs for improved 44 diagnostic accuracy, prognosis prediction, and treatment adjustment using various methods, including 45 machine learning (ML) techniques⁸⁻¹⁰. Literature regarding the utilization of ML algorithms has been 46 rapidly rising, with literature urging more rapid use of such algorithms in oncology to increase diagnostic 47 accuracy or to further improve on the available algorithms $11-13$.

 In this study, I aimed to investigate potential lncRNAs involved in the metastatic progression of PC based on RNA-sequencing (RNA-seq) data. To achieve this objective, I collected publicly available data from the cancer genome atlas (TCGA) for 172 patients and filtered the data according to predefined inclusion and exclusion criteria, which resulted in 151 PC records. PC records were further categorized according to their TNM staging, and tumor data were separated into tumors with metastatic activity (TMAs) and tumors without metastatic activity (TWAs). Using bioinformatics analytic techniques, I

 identified 125 differentially expressed genes (DEGs) among 60,660 genes involved in this study, many of which were novel. I further assessed the functions of this global gene panel using a multiparametric approach.

 Finally, I extracted lncRNA counts from the RNA-seq data from the PC population and further characterized 38 novel lncRNAs that were significantly differentially expressed. To further evaluate their involvement, I used 4 ML algorithms to predict and distinguish between TMAs and TWAs. These algorithms included multivariate logistic regression (LR), support vector machine (SVM), random forest classifier (RFC), and eXtreme Gradient Boosting Classifier (XGBC). I used several techniques to further reduce the bias within the included sample as described in the methodology.

 Training and evaluation of the ML algorithms was performed by separating the dataset from the 38 DEGs into a training set and a testing set to eventually evaluate the performance of each of the models. Out of all the ML algorithms, SVM and RFC were able to predict TMAs and TWAs with 76% accuracy using the 38 lncRNA data, suggesting important implications for the specified set of lncRNAs in PC. To the best of my knowledge, this is the first study to identify the involvement of this specific lncRNA panel in PC, with many novel lncRNAs lacking any studies performed on which.

 The results of this research have important clinical implications, as the novelty of the lncRNAs requires further comprehensive validation and *in vitro* and *in vivo* investigations. The accuracy shown by the ML model suggests that these novel lncRNAs could be used as biomarkers and further targeted for improved diagnosis and outcome in PC patients.

2. Methods

2.1. Data acquisition

75 TCGA database was used for data collection and is available at [https://www.cancer.gov/tcga](https://www.cancer.gov/ccg/research/genome-sequencing/tcga). Exploration of TCGA-PAAD project data to acquire pancreatic RNA-seq data was performed on 25/10/2023. File filters applied included a) Data Category: transcriptome profiling; b) Data Type: Gene Expression Quantification; c) Experimental strategy: RNA-Seq; d) Access: open. The case filters applied included the following: a) primary site: pancreas; b) project: TCGA-PAAD; and c) disease type: ductal and lobular neoplasms, adenomas and adenocarcinomas.

 The inclusion criteria were that for each RNA-seq dataset to be of similar structure, for the predefined PC tumors mentioned in the filters, or regardless of age and gender. Primary tumors, regardless of metastatic stage, were also included. Exclusion criteria included defects in dataset structure, RNA-seq for tumor adjacent tissues, or those that had undergone prior therapy to a potential previous malignancy. I 85 also excluded records with annotations specifying that tumor data were incorrectly labeled in terms of whether the tumor was neoplastic.

 Further categorization was performed for the acquired data using Excel sheets. For TNM subgroup analysis, tumors with staging data were categorized into tumors with metastatic activity, which included those classified as M1, MX/M0 and N1 or above, and tumors without metastatic activity, which included those classified as M0N0. Acquired data were also filtered to include only lncRNA gene expression quantification. This subgrouping was performed prior to DGEA to assess differentially expressed genes between TWAs and TMAs.

93 2.2. Data analysis

94 Bioinformatics analysis was conducted on the data following matching the subjects to the study's 95 inclusion and exclusion criteria. Python v3.11 (available at https://www.python.org/) was used in an 96 Anaconda jupyter lab environment ^{14,15}. To restructure the dataset up for the study population RNA-seq 97 datasets and to import the data into Python, the glob module was used 16 . Data manipulation was 98 performed using pandas library v1.5.3¹⁷. Libraries such as numpy and scipy were also utilized for data 99 processing $18,19$.

100 Differential gene expression analysis (DGEA) was performed using PyDESeq2, an R package 101 implemented in Python that has been suggested to be reliable and comparable to the R package²⁰. The 102 DEGs were matched to gene symbols and further visualized using the matplotlib²¹, seaborn²², and 103 sanbomics²³ packages. PyDeseq2 calculates the significance of genes using the Wald test, performs count 104 normalization using the trimmed mean of M values (TMM), similar to DESeq2, and relies on the 105 statsmodels library^{24,25}. Using count normalization has been shown to have higher accuracy than TPM 106 (transcripts per million) and FPKM (fragments per kilobase of transcript per million fragments mapped)²⁶. 107 A further description of the package is available elsewhere²⁰. Significant differentiation after adjustment 108 of p values was considered at p<0.05 and an absolute log2-fold change (log2FC) of >0.5.

109 A heatmap of the DEGs was made through the matplotlib²¹ package as well. Pearson's correlation 110 coefficient was calculated and mapped for all gene transcript data.

111 2.3. Gene set and ontology enrichment analysis

112 Gene set enrichment analysis (GSEA) is a method of interpreting gene-wide expression profiles²⁷. GSEA was performed using the GSEApy v1.0.6 package, a Rust implementation of GSEA in python, used for performing computation of RNA-seq count data to evaluate predefined gene sets in association with different phenotypes. I ranked expression data using the prerank function available in the package. The

 accuracy of this package has been previously proven, and the method to use it is described extensively 117 elsewhere²⁸.

h.all.v2023.1.Hs.symbols, and miRTarBase_2017.

124 Gene Ontology (GO) is a detailed resource with annotations of gene and gene product functions $30,31$. It provides the potential to describe gene functions by assigning them to specific terms in which the genes are linked, detailing their relationships with each other. GO term enrichment was performed through GSEApy, and the results were extracted through tools available in said package. GO graph was made after 128 extracting enriched GO terms and the source identifiers were insert into AmiGO 32 .

 The false discovery rate (FDR) was considered significant when FDR<0.05. Visualization of GSEA results was performed using tools from GSEApy. Data collected from GSEA results included terms, FDR, enrichment and negative enrichment scores, as well as matched genes. The minimum matching size for gene sets when performing GSEA for the global gene panel was set to 150. However, for the lncRNA panel, the minimum matching size was set to 3, as there were few enriched gene sets.

2.4. Machine learning models

 I employed multivariate LR, SVM, RFC, and XGBC to predict metastatic risk for the population based on the lncRNA gene count data from TCGA. DEGs were extracted from DGEA for use as sole predictors of metastatic progression in the study population. Analysis of the models' accuracy was performed using packages from the scipy, scikit-learn, and matplotlib libraries.

 To train the ML algorithms, data were categorized into a training set (70% of the data) and a testing set (30%). A random state number was set for all the implemented ML models to dictate a specific seed of randomness during the analysis to maintain reproducibility. For binary classification, TNM stage of IIa or below was designated "0" and considered the TWM for the ML algorithms, while TNM stage IIb or above was designated "1" and considered the TMA. The testing sets were hidden from the ML algorithms to evaluate the predictive capacity performance following model training.

 Furthermore, hyperparameter tuning was performed to improve the predictive accuracy of the model. This was done through the GridSearchCV and BayesianSearchCV modules. Fivefold cross-validation was set as a parameter, and data regularization was done through L2 method. The inverse of the regularization strength (or penalty values) was set according to the optimal values found by the search modules specified above. To identify the best parameters, values were also tested over 50 iterations. Moreover, the synthetic minority oversampling technique (SMOTE) was performed to artificially increase TWM population numbers to reduce bias, which has proven to be a powerful tool in improving ML 152 accuracy and addressing imbalanced samples .

 These methods of standardization were performed for all ML algorithms used. ML algorithms used were also provided by the scikit-learn and XGBoost libraries. All of the algorithms consist of supervised 155 machine learning algorithms, and are commonly used for classifications of tumors^{34,35}. Further, L2 156 regularization has been considered to provide improved accuracy of the ML algorithms³⁶.

3. Results

3.1. Primary characteristics of the study population

 Of the 179 retrieved records, 23 were excluded for the following annotations: a) "This case is a neuroendocrine tumor and should not have been included in the PAAD study" (n = 8); b) "Per the PAAD

172

173 **Figure 1.** Flow diagram of the study. Created with Lucidchart[, www.lucidchart.com.](http://www.lucidchart.com/) TCGA: The Cancer

174 Genome Atlas; PAAD: Pancreatic adenocarcinoma; TMA: Tumor with metastatic activity; TWA: Tumor

175 without metastatic activity; DGEA: Differential gene expression analysis; GSEA: Gene set enrichment

176 analysis; ML: Machine learning.

177

183

184 The RNA-seq data included 60,660 gene expression profiles for each of the included patient and 185 control samples. Transcriptomic profiling was performed for the same genes in all patient samples. Of the available transcripts, 16,901 were lncRNAs. After removing lncRNAs with 0 values among all patients, 15,879 lncRNAs remained. All details regarding the included samples are available in **Supplementary Material 1.**

3.2. DGEA and GSEA of all gene transcripts

 A total of 60,660 gene transcripts were filtered following PyDESeq2 analysis, and unavailable values were dropped, resulting in 47,528 transcripts. DGEA revealed 125 differentially expressed genes, asshown in **Table 2,** and the top differentially expressed genes are shown in **Figure 2**. Notably, ADH7, SERPINB13, MIR205HG, NTS, and LINC01300 were the most downregulated genes, with log2FC values of -3.42295, - 3.4189, -3.12513, -3.02808, and -2.72096, respectively. The most upregulated genes were PAX7, AC010789.1, TMPRSS15, DEFA6, and DEFA5 and had log2FC values of 3.149596, 3.506053, 3.538356, 3.594891, and 4.800701, respectively.

Figure 2. Differentially expressed genes in PC. Absolute log2FC>0.5 and adjusted p value<0.05 were

considered as the significance thresholds.

200

 GSEA was subsequently performed, with libraries investigated available in **Supplementary Materials 2**. There were many gene sets enriched with the genes, as many genes were included in the study's gene panel. Notably, several GO terms were enriched, as well as some terms from miRTarBase 2017, as shown in **Figure 3 A and B**. FDR values were significant for the enriched terms (FDR<0.01).

differentiated expression. Here, the gene set was more enriched with the upregulated genes from the

214 and 214 gene panel.

3.3. lncRNA DGEA, correlations, and GSEA

 Further subgroup analysis was performed for lncRNAs in PC, which returned 16,901 gene expression values, for which PyDeseq2 was also used to analyze DEGs. Dropping the 0-sum, duplicate, and unavailable values retrieved 15,568 lncRNAs. Of the lncRNA panel, 38 lncRNAs were significantly differentially expressed (shown in **Figure 4**).

 Figure 4. Differentially expressed LncRNA. Absolute log2FC>0.5 and adjusted p value<0.05 were considered as the significance thresholds.

 Interestingly, the most downregulated genes were LINC01300, DUSP5-DT, AL513128.3, MIR205HG, and AC132192.2, with Log2FC values of -2.55682, -1.55378, -0.70877, -2.68894, and -0.68868, respectively. The most upregulated genes were AC010789.1, LINC00486, ENSG00000261409 (referred to as RF00019), LINC01115, and AC133530.1, with log2FC values of 2.154221, 1.214608, 3.647081, 1.705921, and 2.388161, respectively. Results of DGEA on the lncRNAs are shown in **Table 3**.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297724;](https://doi.org/10.1101/2023.11.01.23297724) this version posted November 3, 2023. The copyright holder for this preprint

- Moreover, since the number of DEGs was feasible, to further visualize the relationship between
- these lncRNAs, each was correlated to the rest, and Pearson's correlation coefficients for all the lncRNAs
- were extracted. The results are visualized in **Figure 5**. A table of all Pearson's correlation coefficients can
- be found in **Supplementary Material 3**.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297724;](https://doi.org/10.1101/2023.11.01.23297724) this version posted November 3, 2023. The copyright holder for this preprint

- **Figure 5.** Hierarchical clustering heatmap of lncRNAs amongst the sample population. The color gradient in the legend refers to Pearson's correlation coefficient. The dendrogram linkage is based on the correlation strength. Geneid: ENSEMBL ID. tw: TWAs; tm: TMAs.
- GSEA and GO analyses were subsequently performed for all the lncRNA data. Due to the lack of studies on the genes of these transcripts, there was no significant enrichment in most databases. Notably, a few terms were enriched from the MSigDB c3.tft.v2023.1.Hs.symbols collection, which is focused on transcription factors. The results of the term enrichment for the top 10 terms in this collection are shown in **Figure 6**, and the results for insignificant term enrichment for other collections and databases can be found in **Supplementary Material 3.**

Figure 6. GSEA of lncRNA data. Terms are more significantly enriched with downregulated genes.

3.4. ML model prediction of PC metastatic potential according to lncRNA gene

expression

 Following the training and testing of each of the ML models, optimizations were performed to find the highest possible accuracy obtainable while reducing bias. Therefore, SMOTE was implemented in all

 the ML algorithms. Reducing sample imbalances improved the predictive accuracy of the utilized algorithms.

 Following SMOTE implementation and thorough hyperparameter tuning, LR demonstrated an accuracy score of 73.91% when distinguishing between TMAs and TWAs when tested, as well as an F1 score of 82.57% and a recall of 90.63%. Regardless, the area under the curve (AUC) for LR was 0.63, which was relatively low. **Figure 7 A and B** show the receiver operating characteristic (ROC) curve and for logistic regression following the implementation of SMOTE and the precision-recall (PR) curve. **C** shows the weight of each lncRNA (feature) in assisting the regression

 84.51% and a recall of 93.75%. **Figure A and B** show the ROC curve as well as the PR curve of the SVM model.

 Fig. 8 A. The SVM algorithm showed an AUC = 0.65, demonstrating modest accuracy of detecting PC cases at TNM stage IIb or above and distinguishing them from less metastatic stages. **B.** SVM model accuracy of predicting positive values in comparison to its recall capacity.

 RFC was one of the most accurate models; after hyperparameter tuning, it returned an accuracy of 76.09% and an F1 score of 81.96%, with a recall of 78.13%. Most importantly, the AUC for this model was 0.75, showing good performance in classifying the tumors. Regardless, the gene panel consisting of 38 genes allowed the ML algorithms to discern advanced TNM stages from relatively early TNM stages in PC. **Figure 9 A and B** also show the RFC model accuracy and PR curve.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.11.01.23297724;](https://doi.org/10.1101/2023.11.01.23297724) this version posted November 3, 2023. The copyright holder for this preprint

 Fig.9 A. The RFC ROC AUC was 0.75, demonstrating acceptable accuracy of detecting PC cases among 278 the other ML algorithms when using the differentially expressed lncRNA counts data, regardless of hyperparameter tuning. **B.** The RFC PR curve showed good recall, albeit with low precision.

 As for XGBC, the model showed 71.73% accuracy; This specific model had the most inconsistency in predicting tumor types following each randomization. **Figure 10 A and B** show the low AUC and its PR curve. Data regarding the evaluation of the ML algorithms are available in **Supplementary Material 4**.

4. Discussion

 Despite advances in diagnostics and therapeutics, PC remains a very challenging condition to treat, 286 with consistently high mortality rates and limited available treatments^{37,38}. Recently, research has focused on identifying prognostic markers for PC, and preclinical studies have identified several prognostic lncRNA

288 signatures^{8,39-41}. LncRNAs have been further suggested to have implications in diagnosis, drug resistance, 289 and therapeutics in PC⁴. However, as most patients are often diagnosed at advanced stages of disease, 290 mutational burdens show complex relationships with lncRNA regulation⁴. Therefore, as the literature 291 suggests, these relationships must be investigated to adjust treatment modalities. This becomes even 292 more crucial in the latter stages of PC.

 This study aimed to provide details regarding DEGs in PC first and then to further analyze differentially expressed lncRNA and assess the diagnostic potential of these lncRNAs during the transition from stage IIa and stage IIb and above. These lncRNAs were extracted after performing DGEA to extract 38 gene transcripts from the global RNA-seq gene panel among 151 patient samples. The diagnostic potential of 297 lncRNAs was assessed using supervised ML techniques to predict metastatic transition. I employed four 298 ML techniques with established accuracy in prediction: LR^{42} , SVM⁴³, RFC⁴³ and XBGC⁴⁴.

299 DGEA of the global gene panel revealed 125 DEGs, many of which were previously uninvestigated. Of 300 the downregulated DEGs, ADH7 was hypothesized to have implications when mutated in pancreatic 301 injury⁴⁵. NTS was also associated with PC 46 . However, SERPINB13 and MIR205HG were previously 302 unexplored in PC but had been discussed in other cancers and were implicated in poor clinical 303 outcomes^{47,48}. No studies are available regarding LINC01300, which warrants further investigation. For the 304 upregulated DEGs, PAX7 was previously reported to have some relationship with cancers, yet studies 305 regarding this specific gene transcript are lacking 49 . For DEFA6 and DEFA5, a report suggested a link 306 between them and clinical outcomes in colorectal cancer⁵⁰. While there were no studies regarding 307 AC010789.1 and TMPRSS15 in PC, some studies linked the potential implications of these genes with other 308 $cancers^{51,52}$.

309 GSEA for the global gene panel revealed several enriched pathways. For example, GO enrichment 310 revealed that the gene panel significantly enriched pathways relevant in the regulation of aerobic

 respiration (GO:1903715), electron transport carrier chain (GO:0022900), and mitochondrial gene expression and translation into RNA transcripts (GO:0140053). Notably, of the miRTarBase enriched 313 pathways, mir-30b-5p microRNA (miRNA) was previously linked to $PC^{53,54}$. While miR-548x-3p has not 314 been studied regarding its function in cancer, miR-144-3p was previously implicated in PC^{55,56}. Additionally, mir-548j-3p had no studies documenting its relationship with cancer. For miR-1468-3p, 316 some studies have suggested it as a biomarker for non-small cell lung cancer and prostate cancer^{57,58}.

 Following the filtering of the global RNA-seq gene panel to lncRNAs exclusively, DGEA revealed 38 differentially expressed lncRNAs, many of which were novel. LINC01300 and MIR205HG, as previously described, in addition to DUSP5-DT and AL513128.3, had no studies in PC, with the latter two lacking any studies on which. In contrast, one report regarding AC132192.2 indicated its relevance in prostate 321 cancer⁵⁹. For the upregulated lncRNAs, AC010789.1, as previously stated, had a report regarding its 322 function in colorectal cancer^{52,60}. LINC00486, RF00019, LINC01115, and AC133530.1 all lack validation 323 studies in PC, but other reports indicate involvement in several diseases, including cancer $61-64$.

 As these novel lncRNAslack studies regarding their functions, GSEA of the selected MSigDB collections returned no significant enrichment but in one transcription factor collection. Notably, the most enriched pathway described genes containing one or more binding regions for a transcription factor that regulates cell fate and controls cell cycle progression from the mitotic phase to interphase, known as TOX high 328 mobility group box family member 4 (TOX4)^{65,66}. Interestingly, lncRNAs enriching this path were primarily downregulated.

 To further explore the significance of the identified 38 lncRNAs, ML algorithms were employed to predict the metastatic state of cancer (designated "0" for stages IIa or below and "1" for stages IIb and above). Of all the algorithms, RFC showed superior accuracy to the other algorithms, showing an AUC of 0.75 and an accuracy of over 76%. While there is much to be understood regarding the functions of the

 identified lncRNA panel, the accuracy shown by RFC reveals important aspects about the involvement of these lncRNAs in PC. This finding warrants further *in vitro* and *in vivo* investigations*.*

 For most of the identified lncRNA panels, this was the first study to uncover their involvement in PC. Regardless, there are many clinical implications for the findings discussed here. The results of this study suggest that the identified lncRNAs could be further utilized to assess the metastatic potential of PC, as well as aid in drug development, since these lncRNAs can be used as drug targets. Since their involvement allowed the prediction and distinction between TNM stages, further investigation of their functions seems crucial.

 Despite the significant findings, this study is not without limitations. First, DEGA was performed for a large number of data, which likely raised data noise. Second, TWAs used as controls were low in number, as most samples had a stage IIb diagnosis, and SMOTE was necessary to utilize for the ML algorithms to reduce bias. Third, there was a lack of normal tissue control samples, which makes it difficult to provide more accurate assessments of the nature of these genes. Last, there might have been biases in the TCGA data from incorrect measurements or sequencing, potentially skewing the results of the RNA-seq data. All of these findings indicate that the findings of this study should be further validated and interpreted with caution.

 Regardless, the presence of evidence regarding some of the identified novel lncRNAs indicates the strength of the rigorous methods used in this study. This further adds to the implications of the findings discussed here and the importance of future research to address these novel lncRNAs as potential markers of metastatic progression in PC.

5. Conclusion

 DGEA utilized in this study identified a set of 38 novel lncRNAs that could contribute to metastatic progression in PC. GSEA was unable to provide sufficient information to further describe the functions of these lncRNA, due to the scarcity of available data relevant to the genes identified. Since different ML algorithms were able to predict metastatic PC with acceptable accuracy and the RFC model predicted PC with 76% accuracy based on the 38 lncRNA DEG panel, it is likely that these genes participate in the metastatic progression of PC, warranting further investigation.

 The significance and importance of this study is represented by the identified novel lncRNA gene set. Metastatic PC lacks sufficient studies regarding the involvement of lncRNAs in tumor proliferation and progression, especially those that use ML algorithms with proven accuracy. This is the first study of its kind to use this methodology to reveal the discussed gene set in PC to distinguish between early-stage and advanced PC. Regardless, more studies are needed to identify the role these genes play in PC metastasis and other cancers.

 Based on the findings of this study, I suggest further research to take place into the role of these genes. *In vitro* and *in vivo* experiments must be conducted to further elucidate the functions these genes may take part in. The accuracy of the ML algorithms to determine PC metastatic potential reveals that these genes could be added to diagnostic methods if their clinical manifestations are confirmed by future studies.

6. Data availability statement

- All raw data acquired from TCGA, in addition to all analyses performed on said data and source code
- utilized to perform the analyses mentioned in the methodology, are available at the link
- https://github.com/hasanalsharoh/PanC.

7. References

- 1. Hu, J.X., Zhao, C.F., Chen, W.B., Liu, Q.C., Li, Q.W., Lin, Y.Y., and Gao, F. (2021). Pancreatic
- cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol *27*, 4298-4321.
- 10.3748/wjg.v27.i27.4298.
- 2. Partyka, O., Pajewska, M., Kwaśniewska, D., Czerw, A., Deptała, A., Budzik, M., Cipora, E., Gąska,
- I., Gazdowicz, L., Mielnik, A., et al. (2023). Overview of Pancreatic Cancer Epidemiology in Europe and
- Recommendations for Screening in High-Risk Populations. Cancers *15*. 10.3390/cancers15143634.
- 3. Andersson, R., Haglund, C., Seppänen, H., and Ansari, D. (2022). Pancreatic cancer the past,
- the present, and the future. Scandinavian Journal of Gastroenterology *57*, 1169-1177.
- 10.1080/00365521.2022.2067786.
- 4. Bin, W., Yuan, C., Qie, Y., and Dang, S. (2023). Long non-coding RNAs and pancreatic cancer: A
- multifaceted view. Biomedicine & Pharmacotherapy *167*, 115601.
- [https://doi.org/10.1016/j.biopha.2023.115601.](https://doi.org/10.1016/j.biopha.2023.115601)
- 5. Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M., Zuk, O., Carey,
- B.W., Cassady, J.P., et al. (2009). Chromatin signature reveals over a thousand highly conserved large
- non-coding RNAs in mammals. Nature *458*, 223-227. 10.1038/nature07672.
- 6. Kore, H., Datta, K.K., Nagaraj, S.H., and Gowda, H. (2023). Protein-coding potential of non-
- canonical open reading frames in human transcriptome. Biochem Biophys Res Commun *684*, 149040.
- 10.1016/j.bbrc.2023.09.068.
- 7. Aswathy, R., and Sumathi, S. (2023). Defining new biomarkers for overcoming therapeutical resistance in cervical cancer using lncRNA. Mol Biol Rep. 10.1007/s11033-023-08864-w.

 8. Zhang, N., Yu, X., Sun, H., Zhao, Y., Wu, J., and Liu, G. (2023). A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.

Medicine (Baltimore) *102*, e35167. 10.1097/md.0000000000035167.

9. Wang, T., Ji, M., Liu, W., and Sun, J. (2023). Development and validation of a novel DNA damage

repair-related long non-coding RNA signature in predicting prognosis, immunity, and drug sensitivity in

uterine corpus endometrial carcinoma. Comput Struct Biotechnol J *21*, 4944-4959.

10.1016/j.csbj.2023.10.025.

10. Zhao, Y., Song, Y., Zhang, Y., Ji, M., Hou, P., and Sui, F. (2023). Screening protective miRNAs and

constructing novel lncRNAs/miRNAs/mRNAs networks and prognostic models for triple-negative breast

cancer. Mol Cell Probes *72*, 101940. 10.1016/j.mcp.2023.101940.

11. Collins, G.S., Whittle, R., Bullock, G.S., Logullo, P., Dhiman, P., de Beyer, J.A., Riley, R.D., and

Schlussel, M.M. (2023). OPEN SCIENCE PRACTICES NEED SUBSTANTIAL IMPROVEMENT IN PROGNOSTIC

MODEL STUDIES IN ONCOLOGY USING MACHINE LEARNING. J Clin Epidemiol.

10.1016/j.jclinepi.2023.10.015.

12. Rasti, P., Wolf, C., Dorez, H., Sablong, R., Moussata, D., Samiei, S., and Rousseau, D. (2019).

Machine Learning-Based Classification of the Health State of Mice Colon in Cancer Study from Confocal

Laser Endomicroscopy. Sci Rep *9*, 20010. 10.1038/s41598-019-56583-9.

- 13. Sharma, A.N., Shwe, S., and Mesinkovska, N.A. (2022). Current state of machine learning for
- non-melanoma skin cancer. Arch Dermatol Res *314*, 325-327. 10.1007/s00403-021-02236-9.
- 14. Anaconda (2016). (Anaconda Software Distribution).
- 15. Kluyver, T., Ragan-Kelley, B., Pérez, F., Granger, B., Bussonnier, M., Frederic, J., Kelley, K.,
- Hamrick, J., Grout, J., Corlay, S., et al. (2016). Jupyter Notebooks a publishing format for reproducible

- computational workflows. In Positioning and Power in Academic Publishing: Players, Agents and
- Agendas, (IOS Press), pp. 87-90. 10.3233/978-1-61499-649-1-87.
- 16. glob Unix style pathname pattern expansion. (2023).
- 17. team, T.p.d. (2023). pandas-dev/pandas: Pandas.
- 18. Harris, C.R., Millman, K.J., van der Walt, S.J., Gommers, R., Virtanen, P., Cournapeau, D., Wieser,
- E., Taylor, J., Berg, S., Smith, N.J., et al. (2020). Array programming with NumPy. Nature *585*, 357-362.
- 10.1038/s41586-020-2649-2.
- 19. Virtanen, P., Gommers, R., Oliphant, T.E., Haberland, M., Reddy, T., Cournapeau, D., Burovski, E.,
- Peterson, P., Weckesser, W., Bright, J., et al. (2020). SciPy 1.0: fundamental algorithms for scientific
- computing in Python. Nature Methods *17*, 261-272. 10.1038/s41592-019-0686-2.
- 20. Boris, M., Maria, T., Vincent, C., and Mathieu, A. (2022). PyDESeq2: a python package for bulk
- RNA-seq differential expression analysis. bioRxiv, 2022.2012.2014.520412. 10.1101/2022.12.14.520412.
- 21. Hunter, J.D. (2007). Matplotlib: A 2D Graphics Environment. Computing in Science & Engineering *9*, 90-95. 10.1109/MCSE.2007.55.
- 22. Waskom, M.L. (2021). seaborn: statistical data visualization. Journal of Open Source Software *6*, 3021. 10.21105/joss.03021.
- 23. Sanborn, M. (2023). sanbomics.
- 24. Seabold, S., and Perktold, J. (2010). Statsmodels: Econometric and statistical modeling with python. In 61. (Austin, TX), pp. 10-25080.
- 25. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome biology *15*, 1-21.

- Doroshow, J.H., and McShane, L.M. (2021). TPM, FPKM, or Normalized Counts? A Comparative Study of
- Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models
- Repository. Journal of Translational Medicine *19*, 269. 10.1186/s12967-021-02936-w.
- 27. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich,
- A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: A
- knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the
- National Academy of Sciences *102*, 15545-15550. 10.1073/pnas.0506580102.
- 28. Fang, Z., Liu, X., and Peltz, G. (2023). GSEApy: a comprehensive package for performing gene set
- enrichment analysis in Python. Bioinformatics *39*, btac757. 10.1093/bioinformatics/btac757.
- 29. Chou, C.H., Shrestha, S., Yang, C.D., Chang, N.W., Lin, Y.L., Liao, K.W., Huang, W.C., Sun, T.H., Tu,

S.J., Lee, W.H., et al. (2018). miRTarBase update 2018: a resource for experimentally validated

microRNA-target interactions. Nucleic Acids Res *46*, D296-d302. 10.1093/nar/gkx1067.

- 30. The Gene Ontology, C., Aleksander, S.A., Balhoff, J., Carbon, S., Cherry, J.M., Drabkin, H.J., Ebert,
- D., Feuermann, M., Gaudet, P., Harris, N.L., et al. (2023). The Gene Ontology knowledgebase in 2023.

Genetics *224*, iyad031. 10.1093/genetics/iyad031.

 31. Ashburner, M., Ball, C.A., Blake, J.A., Botstein, D., Butler, H., Cherry, J.M., Davis, A.P., Dolinski, K., Dwight, S.S., Eppig, J.T., et al. (2000). Gene Ontology: tool for the unification of biology. Nature Genetics

- *25*, 25-29. 10.1038/75556.
- 32. Carbon, S., Ireland, A., Mungall, C.J., Shu, S., Marshall, B., Lewis, S., the Ami, G.O.H., and the

Web Presence Working, G. (2009). AmiGO: online access to ontology and annotation data.

Bioinformatics *25*, 288-289. 10.1093/bioinformatics/btn615.

- 34. Garg, S., and Raghavan, B. (2023). Comparison of machine learning algorithms for the
- classification of spinal cord tumor. Irish Journal of Medical Science (1971 -). 10.1007/s11845-023-03487-

3.

35. Bruno, V., Betti, M., D'Ambrosio, L., Massacci, A., Chiofalo, B., Pietropolli, A., Piaggio, G.,

Ciliberto, G., Nisticò, P., Pallocca, M., et al. (2023). Machine learning endometrial cancer risk prediction

model: integrating guidelines of European Society for Medical Oncology with the tumor immune

- framework. Int J Gynecol Cancer. 10.1136/ijgc-2023-004671.
- 36. Gutman, R., Aronson, D., Caspi, O., and Shalit, U. (2023). What drives performance in machine

learning models for predicting heart failure outcome? Eur Heart J Digit Health *4*, 175-187.

10.1093/ehjdh/ztac054.

 37. Wall, N.R., Fuller, R.N., Morcos, A., and De Leon, M. (2023). Pancreatic Cancer Health Disparity: Pharmacologic Anthropology. Cancers (Basel) *15*. 10.3390/cancers15205070.

38. de Jesus, V.H.F., Mathias-Machado, M.C., de Farias, J.P.F., Aruquipa, M.P.S., Jácome, A.A., and

Peixoto, R.D. (2023). Targeting KRAS in Pancreatic Ductal Adenocarcinoma: The Long Road to Cure.

Cancers (Basel) *15*. 10.3390/cancers15205015.

39. Sun, Y., Yao, L., Man, C., Gao, Z., He, R., and Fan, Y. (2023). Development and validation of

- cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on
- single-cell. Front Immunol *14*, 1220760. 10.3389/fimmu.2023.1220760.

 40. Wang, H., Ding, Y., He, Y., Yu, Z., Zhou, Y., Gong, A., and Xu, M. (2023). LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway. Arch Biochem Biophys *748*, 109783. 10.1016/j.abb.2023.109783.

41. Zhang, R., Wang, X., Ying, X., Huang, Y., Zhai, S., Shi, M., Tang, X., Liu, J., Shi, Y., Li, F., et al.

(2023). Hypoxia-induced long non-coding RNA LINC00460 promotes p53 mediated proliferation and

metastasis of pancreatic cancer by regulating the miR-4689/UBE2V1 axis and sequestering USP10. Int J

Med Sci *20*, 1339-1357. 10.7150/ijms.87833.

42. Tsai, C.W., Chang, W.S., Yueh, T.C., Wang, Y.C., Chin, Y.T., Yang, M.D., Hung, Y.C., Mong, M.C.,

Yang, Y.C., Gu, J., and Bau, D.T. (2023). The Significant Impacts of Interleukin-8 Genotypes on the Risk of

Colorectal Cancer in Taiwan. Cancers (Basel) *15*. 10.3390/cancers15204921.

43. Earnest, A., Tesema, G.A., and Stirling, R.G. (2023). Machine Learning Techniques to Predict

Timeliness of Care among Lung Cancer Patients. Healthcare (Basel) *11*. 10.3390/healthcare11202756.

44. Padwal, M.K., Basu, S., and Basu, B. (2023). Application of Machine Learning in Predicting

Hepatic Metastasis or Primary Site in Gastroenteropancreatic Neuroendocrine Tumors. Current

Oncology *30*, 9244-9261. 10.3390/curroncol30100668.

45. Chiang, C.P., Wu, C.W., Lee, S.P., Chung, C.C., Wang, C.W., Lee, S.L., Nieh, S., and Yin, S.J. (2009).

Expression pattern, ethanol-metabolizing activities, and cellular localization of alcohol and aldehyde

dehydrogenases in human pancreas: implications for pathogenesis of alcohol-induced pancreatic injury.

Alcohol Clin Exp Res *33*, 1059-1068. 10.1111/j.1530-0277.2009.00927.x.

46. Kanellopoulos, P., Nock, B.A., Krenning, E.P., and Maina, T. (2020). Optimizing the Profile of

[(99m)Tc]Tc-NT(7-13) Tracers in Pancreatic Cancer Models by Means of Protease Inhibitors. Int J Mol Sci

21. 10.3390/ijms21217926.

- Hordijk, G.J., Chang, W.S., van der Tweel, I., Tilanus, M.G., and Kummer, J.A. (2009). Downregulation of
- SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical
- outcome. Int J Cancer *125*, 1542-1550. 10.1002/ijc.24507.
- 48. Xu, Y., Yuan, C., Peng, J., Zhou, L., Lin, Y., Wang, Y., Zhang, J., Ma, J., Yin, W., and Lu, J. (2022).
- LncRNA MIR205HG expression predicts efficacy of neoadjuvant chemotherapy for patients with locally
- advanced breast cancer. Genes Dis *9*, 837-840. 10.1016/j.gendis.2021.10.001.
- 49. He, W.A., Berardi, E., Cardillo, V.M., Acharyya, S., Aulino, P., Thomas-Ahner, J., Wang, J.,
- Bloomston, M., Muscarella, P., Nau, P., et al. (2013). NF-κB-mediated Pax7 dysregulation in the muscle
- microenvironment promotes cancer cachexia. J Clin Invest *123*, 4821-4835. 10.1172/jci68523.
- 50. Zhao, X., Lu, M., Liu, Z., Zhang, M., Yuan, H., Dan, Z., Wang, D., Ma, B., Yang, Y., Yang, F., et al.

(2022). Comprehensive analysis of alfa defensin expression and prognosis in human colorectal cancer.

- Front Oncol *12*, 974654. 10.3389/fonc.2022.974654.
- 51. Sun, N.K., Huang, S.L., Lu, H.P., Chang, T.C., and Chao, C.C. (2015). Integrative transcriptomics-

based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the

androgen receptor. Oncotarget *6*, 27065-27082. 10.18632/oncotarget.4824.

52. Duan, W., Kong, X., Li, J., Li, P., Zhao, Y., Liu, T., Binang, H.B., Wang, Y., Du, L., and Wang, C.

(2020). LncRNA AC010789.1 Promotes Colorectal Cancer Progression by Targeting MicroRNA-432-

3p/ZEB1 Axis and the Wnt/β-Catenin Signaling Pathway. Front Cell Dev Biol *8*, 565355.

10.3389/fcell.2020.565355.

524 53. Liu, Y., Xu, G., and Li, L. (2021). LncRNA GATA3-AS1-miR-30b-5p-Tex10 axis modulates

tumorigenesis in pancreatic cancer. Oncol Rep *45*. 10.3892/or.2021.8010.

 54. Chen, K., Wang, Q., Liu, X., Wang, F., Yang, Y., and Tian, X. (2022). Hypoxic pancreatic cancer derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. Int J Biol Sci *18*, 1220-1237. 10.7150/ijbs.67675.

55. Liu, S., Luan, J., and Ding, Y. (2018). miR-144-3p Targets FosB Proto-oncogene, AP-1

Transcription Factor Subunit (FOSB) to Suppress Proliferation, Migration, and Invasion of PANC-1

Pancreatic Cancer Cells. Oncol Res *26*, 683-690. 10.3727/096504017x14982585511252.

56. Yang, J., Cong, X., Ren, M., Sun, H., Liu, T., Chen, G., Wang, Q., Li, Z., Yu, S., and Yang, Q. (2019).

533 Circular RNA hsa_circRNA_0007334 is Predicted to Promote MMP7 and COL1A1 Expression by

Functioning as a miRNA Sponge in Pancreatic Ductal Adenocarcinoma. J Oncol *2019*, 7630894.

10.1155/2019/7630894.

57. Janpipatkul, K., Trachu, N., Watcharenwong, P., Panvongsa, W., Worakitchanon, W.,

Metheetrairut, C., Oranratnachai, S., Reungwetwattana, T., and Chairoungdua, A. (2021). Exosomal

microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients.

Cancer Biomark *31*, 281-294. 10.3233/cbm-203075.

58. Daniel, R., Wu, Q., Williams, V., Clark, G., Guruli, G., and Zehner, Z. (2017). A Panel of MicroRNAs

as Diagnostic Biomarkers for the Identification of Prostate Cancer. Int J Mol Sci *18*.

10.3390/ijms18061281.

 59. Wang, K., Zhong, W., Long, Z., Guo, Y., Zhong, C., Yang, T., Wang, S., Lai, H., Lu, J., Zheng, P., and Mao, X. (2021). 5-Methylcytosine RNA Methyltransferases-Related Long Non-coding RNA to Develop and Validate Biochemical Recurrence Signature in Prostate Cancer. Front Mol Biosci *8*, 775304. 10.3389/fmolb.2021.775304.

61. Zeng, X., Wang, Y., Liu, B., Rao, X., Cao, C., Peng, F., Zhi, W., Wu, P., Peng, T., Wei, Y., et al.

(2023). Multi-omics data reveals novel impacts of human papillomavirus integration on the epigenomic

and transcriptomic signatures of cervical tumorigenesis. J Med Virol *95*, e28789. 10.1002/jmv.28789.

62. Wang, W.F., Zhong, H.J., Cheng, S., Fu, D., Zhao, Y., Cai, H.M., Xiong, J., and Zhao, W.L. (2023). A

nuclear NKRF interacting long noncoding RNA controls EBV eradication and suppresses tumor

progression in natural killer/T-cell lymphoma. Biochim Biophys Acta Mol Basis Dis *1869*, 166722.

10.1016/j.bbadis.2023.166722.

 63. Bi, X.-a., Li, L., Xu, R., and Xing, Z. (2021). Pathogenic Factors Identification of Brain Imaging and Gene in Late Mild Cognitive Impairment. Interdisciplinary Sciences: Computational Life Sciences *13*, 511- 520. 10.1007/s12539-021-00449-0.

 64. Gusev, F.E., Reshetov, D.A., Mitchell, A.C., Andreeva, T.V., Dincer, A., Grigorenko, A.P., Fedonin, G., Halene, T., Aliseychik, M., Filippova, E., et al. (2019). Chromatin profiling of cortical neurons identifies

individual epigenetic signatures in schizophrenia. Transl Psychiatry *9*, 256. 10.1038/s41398-019-0596-1.

65. Yevshin, I., Sharipov, R., Kolmykov, S., Kondrakhin, Y., and Kolpakov, F. (2019). GTRD: a database

- on gene transcription regulation-2019 update. Nucleic Acids Res *47*, D100-d105. 10.1093/nar/gky1128.
- 66. The UniProt, C. (2023). UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids
- Research *51*, D523-D531. 10.1093/nar/gkac1052.